Compass Ion Advisors’s AstraZeneca AZN Stock Holding History

Compass Ion Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,110	Closed	-$210K	–	307
2026 Q2	$210K	Hold	1,110	–	–	0.02%	284
2026 Q1	$219K	Buy	+1,110	New	+$214K	0.02%	262
2024 Q4	–	Sell	-1,365	Closed	-$213K	–	260
2024 Q3	$213K	Sell	1,365 -317	-19%	-$51.2K	0.03%	248
2024 Q2	$228K	Hold	1,682	–	–	0.03%	213
2024 Q1	$228K	Sell	1,682 -118	-7%	-$15.6K	0.03%	213
2023 Q4	$242K	Sell	1,800 -430	-19%	-$55.9K	0.04%	206
2023 Q3	$302K	Buy	+2,230	New	+$305K	0.05%	182

Other funds holding AZN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Compass Ion Advisors's AZN Position: Q3 2026 in Review

Compass Ion Advisors sold out of AstraZeneca (AZN) in Q3 2026, closing a stake of 1,110 shares — an estimated $210K sold.

Compass Ion Advisors first reported a position in AZN in Q3 2023 and held it in 7 quarters. The position peaked at $302K in Q3 2023. 918 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Compass Ion Advisors reported no remaining AstraZeneca position as of Q3 2026 after selling out during the quarter.
Compass Ion Advisors sold 1,110 AstraZeneca shares in Q3 2026, an estimated $210K.
Compass Ion Advisors first reported a position in AstraZeneca in Q3 2023 and held it in 7 quarters.
Compass Ion Advisors's AstraZeneca position peaked at $302K in Q3 2023.
918 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Compass Ion Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.